Evidence map›Paper›PMID 39057500›Full record

ArticleGels (Basel, Switzerland)2024

Comprehensive Biosafety Profile of Carbomer-Based Hydrogel Formulations Incorporating Phosphorus Derivatives.

Khaled Zakzak, Alexandra-Denisa Semenescu, Elena-Alina Moacă, Iasmina Predescu, George Drăghici, Lavinia Vlaia, Vicenţiu Vlaia, Florin Borcan, Cristina-Adriana Dehelean

Abstract read
In one paragraph

Article in Gels (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. CarbopolGels (Basel, Switzerland) · 2026
    Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Khaled ZakzakDepartment of Pharmaceutical Technology, Faculty of Pharmacy, "Victor Babes" University of Medicine and Pharmacy, 2nd Eftimie Murgu Square, 300041 Timisoara, Romania.
Alexandra-Denisa SemenescuDepartment of Toxicology, Drug Industry, Management and Legislation, Faculty of Pharmacy, "Victor Babes" University of Medicine and Pharmacy Timisoara, 2nd Eftimie Murgu Square, 300041 Timisoara, Romania.ORCID 0000-0001-7718-4168
Elena-Alina MoacăDepartment of Toxicology, Drug Industry, Management and Legislation, Faculty of Pharmacy, "Victor Babes" University of Medicine and Pharmacy Timisoara, 2nd Eftimie Murgu Square, 300041 Timisoara, Romania.ORCID 0000-0002-2631-7028
Iasmina PredescuDepartment of Toxicology, Drug Industry, Management and Legislation, Faculty of Pharmacy, "Victor Babes" University of Medicine and Pharmacy Timisoara, 2nd Eftimie Murgu Square, 300041 Timisoara, Romania.
George DrăghiciDepartment of Toxicology, Drug Industry, Management and Legislation, Faculty of Pharmacy, "Victor Babes" University of Medicine and Pharmacy Timisoara, 2nd Eftimie Murgu Square, 300041 Timisoara, Romania.ORCID 0000-0002-8042-0966
Lavinia VlaiaDepartment of Pharmaceutical Technology, Faculty of Pharmacy, "Victor Babes" University of Medicine and Pharmacy, 2nd Eftimie Murgu Square, 300041 Timisoara, Romania.
Vicenţiu VlaiaFormulation and Technology of Drugs Research Center, "Victor Babes" University of Medicine and Pharmacy, 2nd Eftimie Murgu Square, 300041 Timisoara, Romania.
Florin BorcanDepartment of Analytical Chemistry, Faculty of Pharmacy, "Victor Babes" University of Medicine and Pharmacy, 2nd Eftimie Murgu Square, 300041 Timisoara, Romania.ORCID 0000-0003-3406-0303
Cristina-Adriana DeheleanDepartment of Toxicology, Drug Industry, Management and Legislation, Faculty of Pharmacy, "Victor Babes" University of Medicine and Pharmacy Timisoara, 2nd Eftimie Murgu Square, 300041 Timisoara, Romania.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Determining the safety of a newly developed experimental product is a crucial condition for its medical use, especially for clinical trials. In this regard, four hydrogel-type formulations were manufactured, all of which were based on carbomer (Blank-CP940) and encapsulated with caffeine (CAF-CP940), phosphorus derivatives (phenyl phosphinic (CAF-S1-CP940) and 2-carboxyethyl phenyl phosphinic acids (CAF-S2-CP940)). The main aim of this research was to provide a comprehensive outline of the biosafety profile of the above-mentioned hydrogels. The complex in vitro screening (cell viability, cytotoxicity, morphological changes in response to exposure, and changes in nuclei morphology) on two types of healthy skin cell lines (HaCaT-human keratinocytes and JB6 Cl 41-5a-murine epidermal cells) exhibited a good biosafety profile when both cell lines were treated for 24 h with 150 μg/mL of each hydrogel. A comprehensive analysis of the hydrogel's impact on the genetic profile of HaCaT cells sustains the in vitro experiments. The biosafety profile was completed with the in vivo and in ovo assays. The outcome revealed that the developed hydrogels exerted good biocompatibility after topical application on BALB/c nude mice's skin. It also revealed a lack of toxicity after exposure to the hen's chicken embryo. Further investigations are needed, regarding the in vitro and in vivo therapeutic efficacy and safety for long-term use and potential clinical translatability.

Indexed as

BALB/c nude micecaffeineCarbopol 940HET-CAMin ovo assayin vitro assessmentin vivo studyRT-PCRskin biophysical parameters

Identifiers

PMID39057500
PMCPMC11276259

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.